P
Pfizer Portfolio holdings
AUM
$576M
This Quarter Return
+21.95%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$576M
AUM Growth
+$576M
(+15%)
Cap. Flow
-$13M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
96.54%
Holding
21
New
–
Increased
–
Reduced
2
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
NextCure
NXTC
|
$9.57M |
| 2 |
Bolt Biotherapeutics
BOLT
|
$3.43M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioNTech
BNTX
$24B
| $390M | 67.6% | 3,658,361 | – | – |
|
2
Oric Pharmaceuticals
ORIC
$994M
| $54.6M | 9.47% | 5,376,344 | – | – |
|
3
Arvinas
ARVN
$568M
| $25.4M | 4.42% | 3,457,815 | – | – |
|
4
Allogene Therapeutics
ALLO
$251M
| $24.9M | 4.32% | 22,032,040 | – | – |
|
5
Tourmaline Bio
TRML
$601M
| $20.3M | 3.53% | 1,272,214 | – | – |
|
6
Wave Life Sciences
WVE
$1.53B
| $12.2M | 2.12% | 1,875,000 | – | – |
|
7
Pyxis Oncology
PYXS
$79.4M
| $7.74M | 1.34% | 7,032,770 | – | – |
|
8
Cardiff Oncology
CRDF
$140M
| $7.6M | 1.32% | 2,411,575 | – | – |
|
9
Biohaven
BHVN
$1.63B
| $7.13M | 1.24% | 505,645 | – | – |
|
10
Spero Therapeutics
SPRO
$116M
| $6.85M | 1.19% | 2,362,348 | – | – |
|
11
Caribou Biosciences
CRBU
$174M
| $5.91M | 1.03% | 4,690,431 | – | – |
|
12
Celcuity
CELC
$2.17B
| $4.66M | 0.81% | 349,406 | – | – |
|
13
Zura Bio
ZURA
$133M
| $3.12M | 0.54% | 2,970,022 | – | – |
|
14
ESSA Pharma
EPIX
$11.4M
| $2.85M | 0.49% | 1,675,000 | – | – |
|
15
Zentalis Pharmaceuticals
ZNTL
$122M
| $1.11M | 0.19% | 953,834 | – | – |
|
|
16
NextCure
NXTC
$13.5M
| $870K | 0.15% | 157,646 -1,734,117 | -92% | -$9.57M |
|
17
AN2 Therapeutics
ANTX
$30.1M
| $758K | 0.13% | 715,295 | – | – |
|
18
Q32 Bio
QTTB
$20.9M
| $414K | 0.07% | 277,777 | – | – |
|
|
19
Bolt Biotherapeutics
BOLT
$9.85M
| $181K | 0.03% | 31,305 -594,804 | -95% | -$3.43M |
|
20
Ginkgo Bioworks
DNA
$750M
| $32.9K | 0.01% | 2,928 | – | – |
|
21
Senseonics Holdings
SENS
$374M
| $20.7K | ﹤0.01% | 43,426 | – | – |
|